Alkermes Shares Topline Results From Phase 1 Proof-of-concept Study Evaluating ALKS 7290 For Attention-deficit Hyperactivity Disorder, Showing Meaningful Improvements In Patients

Benzinga

2026.09.21 11:06 (GMT+0)

在Benzinga上打开